trending Market Intelligence /marketintelligence/en/news-insights/trending/jjsmezsy-mkpbnng4sxfkq2 content esgSubNav
In This List

Seattle Genetics completes tender offer to acquire Cascadian Therapeutics

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Seattle Genetics completes tender offer to acquire Cascadian Therapeutics

Bothell, Wash.-based Seattle Genetics Inc. completed its tender offer to acquire Cascadian Therapeutics Inc. for $614 million.

Seattle Genetics expects to close the merger March 9, with Cascadian becoming a wholly owned subsidiary of the company.

Following completion of the merger, Cascadian's common stock will no longer be listed for trading on the Nasdaq.

Seattle-based Cascadian is a biopharmaceutical company focused on cancer treatments and is developing tucatinib, an investigational treatment of HER2-positive metastatic breast cancer, including patients whose disease may have spread to the brain.